Plantar Fasciitis Treatments | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0235 governing plantar fasciitis treatments, with an effective date of April 29, 2026. Here's what billing teams need to do.

Aetna's plantar fasciitis coverage policy under CPB 0235 has been updated. The policy covers a range of treatments for plantar fasciitis and heel pain — a condition that generates significant claim volume across podiatry, orthopedics, physical therapy, and sports medicine practices. The policy document does not publish specific CPT or HCPCS codes in the available data. We'll walk through what this means for your plantar fasciitis billing and what steps to take before the effective date.

Aetna Plantar Fasciitis Coverage Criteria and Medical Necessity Requirements 2026

Plantar fasciitis is one of the most billed musculoskeletal conditions in outpatient podiatry and orthopedics. Aetna's CPB 0235 has long drawn lines between treatments it considers medically necessary and those it considers experimental or unproven. A modification to this coverage policy means those lines have shifted — and claims that were clean before April 29, 2026 may not be clean after.

The core of Aetna's medical necessity standard for plantar fasciitis has historically required documented conservative treatment failure. That means your documentation needs to show the patient tried first-line therapies — stretching, orthotics, NSAIDs, physical therapy — before Aetna approves more advanced interventions. If your notes don't tell that story clearly, you're looking at a claim denial.

Prior authorization requirements under CPB 0235 apply to several interventions beyond conservative care. Extracorporeal shock wave therapy (ESWT) is a classic example — Aetna has historically required prior auth for this procedure, and billing teams that skip that step get burned. With this modification in effect, check whether prior authorization requirements have expanded to additional treatments in your practice's mix.

Medical necessity documentation should be updated now. Don't wait until after the effective date to audit your intake forms, treatment notes, and referral patterns. Aetna reviewers look for specific documentation elements when adjudicating these claims, and a vague "failed conservative care" notation won't hold up under post-payment review.

Aetna Plantar Fasciitis Exclusions and Non-Covered Indications

Aetna's CPB 0235 has historically classified several plantar fasciitis treatments as experimental, investigational, or not medically necessary. This is where the policy gets contentious — and where your claim denial risk is highest.

Platelet-rich plasma (PRP) injections for plantar fasciitis have been a consistent non-covered indication under Aetna's policy. Aetna has not recognized PRP as proven effective for plantar fasciitis based on clinical evidence, and this modification is unlikely to reverse that position. If you bill PRP injections for Aetna members without an explicit coverage determination in hand, expect denial.

Certain surgical interventions, including endoscopic plantar fasciotomy, have had conditional coverage status under CPB 0235. Coverage typically requires exhausting a defined period of conservative therapy — often six months or more — and documenting that failure. Billing for surgical intervention without that documented history is a fast path to a denial and a potential audit flag.

Prolotherapy, dry needling for fascial release, and some regenerative medicine approaches have historically fallen into the experimental category under this coverage policy. If you offer these services, check CPB 0235 directly for the current classification. The modification on April 29, 2026 may have shifted any of these designations.

Coverage Indications at a Glance

The specific policy document does not provide code-level or indication-level detail in the available data for this modification. The table below reflects Aetna's historically documented positions under CPB 0235 — validate each row against the current policy before using for billing decisions.

Pull the current CPB 0235 document directly from Aetna to confirm each of these designations as of April 29, 2026. Policy modifications can shift individual indications without changing the overall structure.

Aetna Plantar Fasciitis Billing Guidelines and Action Items 2026

This is where you turn policy analysis into action. The modification effective April 29, 2026 requires specific steps from your billing team before that date — not after.

CPT, HCPCS, and ICD-10 Codes for Plantar Fasciitis Treatments Under CPB 0235

The policy data available for this modification does not include specific CPT, HCPCS, or ICD-10 codes. Aetna has not published code-level detail in the accessible version of this policy update.

This is not unusual for CPB modifications — Aetna sometimes updates criteria language without changing the code list, or updates the code list as an appendix that doesn't surface in summary data. Either way, your billing team should not assume the code list is unchanged.

What to do: Access the full CPB 0235 document directly from Aetna's Clinical Policy Bulletins library. The complete document will list every applicable procedure code and diagnosis code. Compare the current version against the prior version — look specifically at the code tables at the end of the bulletin, which are where additions and deletions typically appear.

Common procedure codes associated with plantar fasciitis treatment — including codes for ESWT, corticosteroid injections, orthotics, and surgical procedures — should all be verified against the current CPB 0235 before billing. Do not infer coverage from prior-version code lists.

If you need a line-by-line diff showing exactly what changed between the previous version of CPB 0235 and the April 29, 2026 version, that's precisely what PayerPolicy tracks. See the section below.